Literature DB >> 3873124

New concepts in the control of ocular inflammation.

P I Murray, A H Rahi.   

Abstract

Recent advances in the field of cellular immunology have enabled us to recognise a complex homeostatic mechanism controlling inflammation, allowing us to understand the aetiopathogenesis of many systemic disease processes. This immune regulatory mechanism involves the interaction of positive and negative messages passing between the different subsets of peripheral blood lymphocytes. Quantitative or qualitative defects in the suppressor cell subset of thymus derived T-lymphocytes are believed to be responsible (at least in part) for chronic inflammation and autoimmune disease. A variety of peripheral blood lymphocyte parameters were examined in four ill-understood inflammatory ophthalmological conditions: acute anterior uveitis, heterochromic cyclitis, acute lepromatous uveitis and Mooren's ulcer. Defects in the number or function of suppressor T-cells were found in all conditions studied. These findings make it possible to explain some of the immunological aberrations previously reported in these conditions. As abnormalities have been found in the immune regulatory mechanism of patients with inflammatory eye conditions of unknown aetiology, the way is now open to explore new lines of treatment using drugs which have the properties to allow selective manipulation of T-lymphocyte subsets.

Entities:  

Mesh:

Year:  1985        PMID: 3873124

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  3 in total

1.  Activated T lymphocytes in uveitis.

Authors:  J Deschênes; D H Char; S Kaleta
Journal:  Br J Ophthalmol       Date:  1988-02       Impact factor: 4.638

2.  Serum autoantibodies and uveitis.

Authors:  P Murray
Journal:  Br J Ophthalmol       Date:  1986-04       Impact factor: 4.638

3.  Corneal perforation in Mooren's ulcer--immunological and clinical follow-up.

Authors:  A Parunović; S Brkić; S Vucković
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.